NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Biotechnology

NewLimit

Brian Armstrong

Alex Kim

Burak Dura

The Research and Development Team at NewLimit focuses on pioneering innovative therapies to combat age-related diseases by reprogramming the epigenome. Utilizing advanced techniques in functional genomics and machine learning, the team conducts large-scale experiments to uncover the mechanisms of epigenetic aging. Their collaborative efforts drive the discovery and development of groundbreaking medicines aimed at enhancing human healthspan.

Research and Development Team

About

Team members